Protein kinase cβ is an effective target for chemoprevention of colon cancer

Cancer Research

Volumn 69, Issue 4, 2009, Pages 1643-1650

  Fields, Alan P ^a   Calcagno, Shelly R ^a   Krishna, Murli ^b   Rak, Sofija ^a   Leitges, Michael ^c   Murray, Nicole R ^a,d  

^a Departments of Cancer Biology   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; BETA CATENIN; CYCLOOXYGENASE 2; ENZASTAURIN; PROTEIN KINASE C BETA; VASCULOTROPIN; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; INDOLE DERIVATIVE; PROTEIN KINASE C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLON ADENOMA; COLON CARCINOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG TARGETING; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; APOPTOSIS; C57BL MOUSE; CELL DIFFERENTIATION; CELL DIVISION; COLON TUMOR; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; EPITHELIUM CELL; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; CELL DIFFERENTIATION; CELL DIVISION; COLONIC NEOPLASMS; ENZYME INHIBITORS; EPITHELIAL CELLS; FEMALE; HUMANS; INDOLES; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE C;

EID: 60549085252     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3187     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57: 43-66.
2. Baranda J, Williamson S. The new paradigm in the treatment of colorectal cancer: are we hitting the right target? Expert Opin Investig Drugs 2007;16:311-24.
3. Gokmen-Polar Y, Murray NR, Velasco MA, Gatalica Z, Fields AP. Elevated protein kinase C βII is an early promotive event in colon carcinogenesis. Cancer Res 2001;61:1375-81.
4. Liu Y, Su W, Thompson EA, Leitges M, Murray NR, Fields AP. Protein kinase CβII regulates its own expression in rat intestinal epithelial cells and the colonic epithelium in vivo. J Biol Chem 2004;279:45556-63.
5. Murray NR, Davidson LA, Chapkin RS, Clay Gustafson W, Schattenberg DG, Fields AP. Overexpression of protein kinase CβII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J Cell Biol 1999;145:699-711.
6. Murray NR, Weems J, Braun U, Leitges M, Fields AP. Protein kinase CβII and PKCι/λ: collaborating partners in colon cancer promotion and progression. Cancer Res 2009;69:656-62.
7. Murray NR, Weems C, Chen L, et al. Protein kinase CβII and TGFβRII in ω-3 fatty acid-mediated inhibition of colon carcinogenesis. J Cell Biol 2002;157:915-20.
8. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cβ-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:7462-9.
9. Moreau AS, Jia X, Ngo HT, et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 2007;109:4964-72.
10. Podar K, Raab MS, Zhang J, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 2007;109:1669-77.
11. Keyes KA, Mann L, Sherman M, et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 2004;53:133-40.
12. Carducci MA, Musib L, Kies MS, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase Cβ inhibitor, in patients with advanced cancer. J Clin Oncol 2006;24:4092-9.
13. Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of enzastaurin, a protein kinase C β inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007;25:1741-6.
14. Fine HA, Kim L, Royce C, et al. Results from phase II trial of Enzastaurin (LY317615) in patients with recurrent high grade gliomas. Journal of Clinical Oncology ASCO Annual Meeting Proceedings; 2005. p. 1504.
15. Morschhauser F, Seymour JF, Kluin-Nelemans HC, et al. A phase II study of enzastaurin, a protein kinase Cβ inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol 2008;19:247-53.
16. Leitges M, Schmedt C, Guinamard R, et al. Immunodeficiency in protein kinase cβ-deficient mice. Science 1996;273:788-91.
17. Calcagno SR, Li S, Colon M, et al. Oncogenic K-ras promotes early carcinogenesis in the mouse proximal colon. Int J Cancer 2008;122:2462-70.
18. Whiteford CC, Bilke S, Greer BT, et al. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res 2007;67:32-40.
19. Regala RP, Thompson EA, Fields AP. Atypical protein kinase Cι expression and aurothiomalate sensitivity in human lung cancer cells. Cancer Res 2008;68:5888-95.
20. Regala RP, Weems C, Jamieson L, Copland JA, Thompson EA, Fields AP. Atypical protein kinase Cι plays a critical role in human lung cancer cell growth and tumorigenicity. J Biol Chem 2005;280:31109-15.
21. Su W, Bush CR, Necela BM, et al. Differential expression, distribution, and function of PPAR{γ}in the proximal and distal colon. Physiol Genomics 2007;30:342-53.
22. Welch PA, Sinha VP, Cleverly AL, Darstein C, Flanagan SD, Musib LC. Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-β inhibitor, in healthy subjects. J Clin Pharmacol 2007;47:1138-51.
23. Guindi M, Riddell RH. The pathology of epithelial pre-malignancy of the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2001;15:191-210.
24. Dudek AZ, Zwolak P, Jasinski P, et al. Protein kinase C-β inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis. Invest New Drugs 2008;26:13-24.
25. Yu W, Murray NR, Weems C, et al. Role of cyclo-oxygenase 2 in protein kinase CβII-mediated colon carcinogenesis. J Biol Chem 2003;278:11167-74.
26. Zhang J, Anastasiadis PZ, Liu Y, Thompson EA, Fields AP. Protein kinase C (PKC) βII induces cell invasion through a Ras/Mek-, PKCι/Rac 1-dependent signaling pathway. J Biol Chem 2004;279:22118-23.
27. Takahashi M, Nakatsugi S, Sugimura T, Wakabayashi K. Frequent mutations of the β-catenin gene in mouse colon tumors induced by azoxymethane. Carcinogenesis 2000;21:1117-20.
28. Pennisi E. How a growth control path takes a wrong turn to cancer. Science 1998;281:1438-9, 41.
29. Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P. Downregulation of β-catenin by human Axin and its association with the APC tumor suppressor, β-catenin and GSK3β. Curr Biol 1998;8:573-81.
30. Goode N, Hughes K, Woodgett JR, Parker PJ. Differential regulation of glycogen synthase kinase-3β by protein kinase C isotypes. J Biol Chem 1992;267:16878-82.
31. Takayama T, Ohi M, Hayashi T, et al. Analysis of K-ras, APC, β-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. Gastroenterology 2001;121:599-611.
32. Slattery ML, Anderson K, Curtin K, et al. Lifestyle factors and Ki-ras mutations in colon cancer tumors. Mutat Res 2001;483:73-81.
33. Haigis KM, Kendall KR, Wang Y, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008;40:600-8.
34. Verheul HM, Pinedo HM. The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors. Clin Breast Cancer 2000;1 Suppl 1:S80-4.
35. Easwaran V, Lee SH, Inge L, et al. β-Catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res 2003;63:3145-53.
36. Kelly DJ, Buck D, Cox AJ, Zhang Y, Gilbert RE. Effects on protein kinase C-β inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy. Am J Physiol Renal Physiol 2007;293:F565-74.
37. Ohshiro Y, Ma RC, Yasuda Y, et al. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cβ-null mice. Diabetes 2006;55:3112-20.
38. Mulkeen AL, Silva T, Yoo PS, et al. Short interfering RNA-mediated gene silencing of vascular endothelial growth factor: effects on cellular proliferation in colon cancer cells. Arch Surg 2006;141:367-74;discussion 74.
39. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur J Clin Invest 2007;37:878-86.
40. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004;10:8465-71.
41. Shao J, Sheng H, Aramandla R, et al. Coordinate regulation of cyclooxygenase-2 and TGF-β1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis 1999;20:185-91.
42. Fukutake M, Nakatsugi S, Isoi T, et al. Suppressive effects of nimesulide, a selective inhibitor of cyclo-oxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis 1998;19:1939-42.
43. Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000;60:293-7.
44. Koehne CH, Dubois RN. COX-2 inhibition and colorectal cancer. Semin Oncol 2004;31:12-21.
45. Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006;113:1578-87.
46. Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006;114:1028-35.
47. Araki Y, Okamura S, Hussain SP, et al. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 2003;63:728-34.
48. Shao J, Jung C, Liu C, Sheng H. Prostaglandin E2 stimulates the β-catenin/T cell factor-dependent transcription in colon cancer. J Biol Chem 2005;280:26565-72.
49. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-β-catenin signaling axis. Science 2005;310:1504-10.